Cargando…

Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study

BACKGROUND: Controlled trials have demonstrated the efficacy of antihistamines in the treatment of chronic idiopathic urticaria. Second-generation antihistamines are recommended as first-line therapy for chronic idiopathic urticaria. The purpose of this study was to determine the effect of deslorata...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Harold, Lynde, Charles
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773525/
https://www.ncbi.nlm.nih.gov/pubmed/19915710
http://dx.doi.org/10.1111/j.1753-5174.2008.00010.x
_version_ 1782173873118117888
author Kim, Harold
Lynde, Charles
author_facet Kim, Harold
Lynde, Charles
author_sort Kim, Harold
collection PubMed
description BACKGROUND: Controlled trials have demonstrated the efficacy of antihistamines in the treatment of chronic idiopathic urticaria. Second-generation antihistamines are recommended as first-line therapy for chronic idiopathic urticaria. The purpose of this study was to determine the effect of desloratadine, a newer, nonsedating, second-generation antihistamine, on symptoms of chronic idiopathic urticaria, disease severity, and quality of life (QoL). METHODS: In an open-label, observational, multicenter study, 348 subjects with chronic idiopathic urticaria were given 5 mg of desloratadine once daily for 2 weeks. Outcome measures included change from baseline at Day 14 using the Aerius Quality of Life Questionnaire (AEQLQ); change from baseline in pruritus score, number and maximum size of hives, sleep quality, and activity impairment; and subjects' response to therapy. RESULTS: Desloratadine significantly decreased subjects' overall condition and symptom scores from baseline to Day 14 (2.19 ± [SD] 0.66 and 1.14 ± 0.89, respectively; P < 0.0001). Desloratadine treatment significantly improved all 10 AEQLQ domain scores from baseline to Day 7 and Day 14 (P < 0.0001). Sleep disturbance scores decreased 40% from baseline to Day 7 (1.42 ± 1.03 to 0.85 ± 0.89, respectively), and interference with daily outdoor activity scores showed a 41% decrease from baseline to Day 7 (1.11 ± 0.98 to 0.66 ± 0.90) (P < 0.0001 for both). There were significant reductions in itching, size of hives, and hive score at both Days 7 and 14. Treatment resulted in moderate, marked, or complete relief of symptoms in 76.2% of subjects. Desloratadine was well tolerated, with no adverse events reported. CONCLUSION: In an open-label, observational study, desloratadine 5 mg once daily significantly decreased symptoms of chronic idiopathic urticaria and improved subject QoL.
format Text
id pubmed-2773525
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Blackwell Publishing Inc
record_format MEDLINE/PubMed
spelling pubmed-27735252009-11-13 Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study Kim, Harold Lynde, Charles Arch Drug Inf Original Articles BACKGROUND: Controlled trials have demonstrated the efficacy of antihistamines in the treatment of chronic idiopathic urticaria. Second-generation antihistamines are recommended as first-line therapy for chronic idiopathic urticaria. The purpose of this study was to determine the effect of desloratadine, a newer, nonsedating, second-generation antihistamine, on symptoms of chronic idiopathic urticaria, disease severity, and quality of life (QoL). METHODS: In an open-label, observational, multicenter study, 348 subjects with chronic idiopathic urticaria were given 5 mg of desloratadine once daily for 2 weeks. Outcome measures included change from baseline at Day 14 using the Aerius Quality of Life Questionnaire (AEQLQ); change from baseline in pruritus score, number and maximum size of hives, sleep quality, and activity impairment; and subjects' response to therapy. RESULTS: Desloratadine significantly decreased subjects' overall condition and symptom scores from baseline to Day 14 (2.19 ± [SD] 0.66 and 1.14 ± 0.89, respectively; P < 0.0001). Desloratadine treatment significantly improved all 10 AEQLQ domain scores from baseline to Day 7 and Day 14 (P < 0.0001). Sleep disturbance scores decreased 40% from baseline to Day 7 (1.42 ± 1.03 to 0.85 ± 0.89, respectively), and interference with daily outdoor activity scores showed a 41% decrease from baseline to Day 7 (1.11 ± 0.98 to 0.66 ± 0.90) (P < 0.0001 for both). There were significant reductions in itching, size of hives, and hive score at both Days 7 and 14. Treatment resulted in moderate, marked, or complete relief of symptoms in 76.2% of subjects. Desloratadine was well tolerated, with no adverse events reported. CONCLUSION: In an open-label, observational study, desloratadine 5 mg once daily significantly decreased symptoms of chronic idiopathic urticaria and improved subject QoL. Blackwell Publishing Inc 2008-09 /pmc/articles/PMC2773525/ /pubmed/19915710 http://dx.doi.org/10.1111/j.1753-5174.2008.00010.x Text en © 2008, Archives of Drug Information http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Articles
Kim, Harold
Lynde, Charles
Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study
title Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study
title_full Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study
title_fullStr Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study
title_full_unstemmed Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study
title_short Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study
title_sort impact of desloratadine on symptoms and quality of life in subjects with chronic idiopathic urticaria: a multicenter, practice-based study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773525/
https://www.ncbi.nlm.nih.gov/pubmed/19915710
http://dx.doi.org/10.1111/j.1753-5174.2008.00010.x
work_keys_str_mv AT kimharold impactofdesloratadineonsymptomsandqualityoflifeinsubjectswithchronicidiopathicurticariaamulticenterpracticebasedstudy
AT lyndecharles impactofdesloratadineonsymptomsandqualityoflifeinsubjectswithchronicidiopathicurticariaamulticenterpracticebasedstudy